Fungal secondary metabolites as a potential inhibitor of T315I- BCR::ABL1 mutant in chronic myeloid leukemia by molecular docking, molecular dynamics simulation and binding free energy exploration approaches

Dilinazi Abulaiti, Niluopaer Tuerxun, Huan Wang, Lina Ma, Fang Zhao, Yang Liu, Jianping Hao · 2024

Read Fungal secondary metabolites as a potential inhibitor of T315I- BCR::ABL1 mutant in chronic myeloid leukemia by molecular docking, molecular dynamics simulation and binding free energy exploration approaches by Dilinazi Abulaiti, Niluopaer Tuerxun, Huan Wang, Lina Ma, Fang Zhao, Yang Liu, Jianping Hao (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11617718.txt.

Description

Dilinazi Abulaiti and co-authors screen fungal compounds in the computer for one that can block a drug-resistant leukemia protein, in a 2024 study. Chronic myeloid leukemia is driven by the BCR-ABL1 fusion protein. A mutation called T315I shuts out many targeted drugs. Fungal products are a rich source of drug-like molecules. None is yet approved for this leukemia.

About two thousand fungal metabolites were docked against the mutant protein. Promising hits passed drug-likeness and safety screens. Molecular dynamics simulations tested whether binding stays stable. Free energy estimates ranked the survivors. The pipeline narrows a vast library to a few leads. Wet-lab tests are the necessary next step. The study shows how computation can front-run costly screening.

Catalog record

CREATORDilinazi Abulaiti, Niluopaer Tuerxun, Huan Wang, Lina Ma, Fang Zhao, Yang Liu, Jianping Hao
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE70 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11617718

Browse the full library · About the Tower of Babel